Scinai Immunotherapeutics to Participate in BIO-Europe Spring 2026

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Mar 19 2026

0mins

Should l Buy SCNI?

Scinai Immunotherapeutics announced its participation in BIO-Europe Spring 2026, taking place March 23-25 in Lisbon, Portugal. During the conference, the team will meet with pharmaceutical and biotechnology companies, investors, and prospective clients to advance both Scinai's innovative R&D pipeline and its integrated CDMO offering. "BIO-Europe Spring marks an important milestone for Scinai as we present our expanded capabilities following the Recipharm transaction," said Amir Reichman, Chief Executive Officer of Scinai. "We are uniquely positioned to partner with biotech and pharma companies across the full lifecycle of their products, from early-stage development through clinical and into commercial manufacturing, while also advancing a differentiated pipeline of immunology therapeutics. We look forward to engaging with partners who are seeking both innovation and execution."

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SCNI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SCNI

About SCNI

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Scinai Immunotherapeutics Completes CDMO Business Reorganization

Apr 06 2026PRnewswire

Strategic Reorganization Completed: Scinai Immunotherapeutics has announced the completion of a strategic reorganization of its CDMO business, establishing a dedicated CDMO platform and streamlining its R&D organization to enhance capital efficiency and operational focus, thereby creating value for stakeholders.
CDMO Platform Development: The newly formed Scinai Biopharma Services Ltd. consolidates all CDMO-related operations, including personnel, infrastructure, and customer contracts, creating a fully integrated CDMO platform capable of supporting customer programs from early-stage development through to commercial production.
Lean R&D Structure: By transferring CDMO-related assets and personnel, Scinai Immunotherapeutics has achieved a significantly leaner R&D structure, allowing non-core infrastructure and operational functions to directly support revenue-generating activities, thus improving capital efficiency.
2026 Strategic Goals: The company has set strategic objectives for 2026 aimed at driving growth in the biopharmaceutical sector through a focused CDMO business and efficient R&D pipeline, while collaboration with Recipharm is expected to further enhance its market competitiveness.

Scinai Immunotherapeutics Completes CDMO Business Reorganization

Apr 06 2026Newsfilter

Strategic Reorganization: Scinai Immunotherapeutics has completed a strategic reorganization of its CDMO business, establishing a dedicated CDMO platform while streamlining its R&D organization to enhance capital efficiency and operational focus, thereby creating value for stakeholders.
CDMO Platform Development: The newly formed Scinai Biopharma Services Ltd. consolidates all CDMO-related operations, including personnel, infrastructure, and customer contracts, creating a fully integrated CDMO platform designed to support customer programs throughout the entire lifecycle.
Revenue Targets: The company anticipates approximately $5 million in CDMO revenues for 2026, leveraging its collaboration with Recipharm to expand its customer base in the U.S. and Europe, thus driving business growth.
Optimized R&D Structure: Following the reorganization, Scinai Immunotherapeutics operates with a leaner R&D structure focused on high-value development projects, enhancing capital allocation efficiency through non-dilutive funding strategies to support early-stage development.

Scinai Immunotherapeutics Financial Overview

Apr 02 2026seekingalpha

Cash Position: As of December 31, 2025, Scinai Immunotherapeutics reported cash, cash equivalents, and restricted cash totaling $1.8 million, down from $2.1 million as of December 31, 2024, indicating challenges in liquidity management.
Revenue Growth: For FY 2025, Scinai achieved revenue of $1.3 million, representing an 85.7% year-over-year increase, which highlights significant progress in market demand and product promotion, potentially enhancing its attractiveness for future investments.
Nasdaq Notice: The company received a notice from Nasdaq regarding minimum bid price requirements, which could negatively impact its stock price and market confidence, compelling the company to take measures to maintain its listing status.
Financial Transparency: The financial information released by the company reveals a contradiction between revenue growth and cash flow management, necessitating stronger financial strategies to ensure sustainable development moving forward.

Scinai Immunotherapeutics Reports 2025 Financial Highlights

Apr 01 2026PRnewswire

Revenue Growth: Scinai reported revenues of $1.3 million for 2025, an 85% increase from $0.7 million in 2024, indicating ongoing expansion of its CDMO activities, although the overall financial situation remains challenging.
R&D Expense Reduction: R&D expenses decreased to $2.4 million in 2025 from $5.5 million in 2024, primarily due to a reallocation of employee and facility costs, which may impact future innovation capabilities.
Widening Net Loss: The company reported a net loss of $8.3 million in 2025, compared to a net income of $4.8 million in 2024, reflecting the absence of financial gains from loan conversions that occurred in 2024, highlighting pressure on profitability.
Strategic Acquisition: In February 2026, Scinai completed the acquisition of Recipharm's manufacturing site in Israel, expanding its capabilities into small-molecule development and manufacturing, thereby strengthening its position as an integrated CDMO platform, which is expected to enhance customer service capabilities and broaden market reach.

Scinai Immunotherapeutics Reports 2025 Financial Highlights and Strategic Developments

Apr 01 2026Newsfilter

Doubling CDMO Revenue: In 2025, Scinai's CDMO revenue doubled year-over-year to $1.3 million, reflecting ongoing commercial traction despite a net loss of $8.3 million, indicating challenges in profitability amidst growth.
Strategic Acquisition and Collaboration: The company completed the acquisition of Recipharm's manufacturing site in Israel in 2026 and entered into a strategic collaboration, enhancing its manufacturing capabilities and broadening service offerings, marking a significant step in its integrated drug development lifecycle.
Optimized R&D Spending: R&D expenses decreased to $2.4 million in 2025 from $5.5 million in 2024, primarily due to a reallocation of employee and facility costs, which may impact future innovation capabilities despite improving operational efficiency.
Non-Dilutive Funding Strategy: The company resubmitted its FENG grant application seeking €12 million to support PC111 and IL-17 programs, demonstrating a strategic shift towards capital-efficient funding mechanisms aimed at advancing key projects without diluting shareholder equity.